GG 705 (Ranitidine 150 mg)
Pill imprint GG 705 has been identified as Ranitidine hydrochloride 150 mg.
Ranitidine is used in the treatment of gerd; erosive esophagitis; stomach ulcer; gastric ulcer maintenance treatment; duodenal ulcer (and more), and belongs to the drug class H2 antagonists. There is no proven risk in humans during pregnancy. Ranitidine 150 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for GG 705 (Ranitidine 150 mg)
- 150 mg
- 8.00 mm
- Rx and/or OTC
- Drug Class:
- H2 antagonists
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- N - Not a controlled drug
- Sandoz Pharmaceuticals Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- D&C Red No. 30
hypromellose 2910 (3 mPa.s)
sodium starch glycolate type A potato
|NDC Code||Manufacturer / Repackager|
|51079-0879||UDL Laboratories Inc|
|63739-0266||McKesson Packaging Services|
|66267-0188||Nucare Pharmaceuticals Inc (repackager)|
|57866-6930||Direct Dispensing Inc (repackager)|
|67544-0049||Prepak Systems Inc (repackager)|
|21695-0109||Rebel Distributors Corp (repackager)|
|23490-6249||Palmetto State Pharmaceuticals Inc (repackager)|
Note: Inactive ingredients may vary.